{"id":"https://openalex.org/W4411475014","doi":"https://doi.org/10.1016/s0140-6736(25)01185-7","title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study","display_name":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study","alternate_titles":[],"publication_year":2025,"publication_date":"2025-06-20","ids":{"openalex":"https://openalex.org/W4411475014","doi":"https://doi.org/10.1016/s0140-6736(25)01185-7","pmid":"https://pubmed.ncbi.nlm.nih.gov/40550231"},"language":"en","primary_location":{"id":"doi:10.1016/s0140-6736(25)01185-7","doi":"https://doi.org/10.1016/s0140-6736(25)01185-7","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0140-6736(25)01185-7","pdf_url":null,"source":{"id":"https://openalex.org/S49861241","display_name":"The Lancet","issn_l":"0099-5355","issn":["0099-5355","0140-6736","1474-547X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4411475014"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020283181","display_name":"Kirsten Dahl","orcid":"https://orcid.org/0000-0001-5063-1554","observed_orcids":["https://orcid.org/0000-0001-5063-1554"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":true,"raw_author_name":"Kirsten Dahl","raw_affiliation_strings":["Novo Nordisk, M\u00e5l\u00f8v, Denmark. Electronic address: kdhl@novonordisk.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk, M\u00e5l\u00f8v, Denmark. Electronic address: kdhl@novonordisk.com","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109127953","display_name":"S\u00f8ren Toubro","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"S\u00f8ren Toubro","raw_affiliation_strings":["Novo Nordisk, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069346863","display_name":"Sohan Dey","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160744","display_name":"Novo Nordisk (India)","ror":"https://ror.org/05dw07152","country_code":"IN","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963","https://openalex.org/I4210160744"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Sohan Dey","raw_affiliation_strings":["Novo Nordisk GBS India, Bangalore, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk GBS India, Bangalore, India","institution_ids":["https://openalex.org/I4210160744"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043562896","display_name":"Ruben Duque do Vale","orcid":"https://orcid.org/0000-0002-6640-1945","observed_orcids":["https://orcid.org/0000-0002-6640-1945"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Ruben Duque do Vale","raw_affiliation_strings":["Novo Nordisk, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019076349","display_name":"Anne Flint","orcid":"https://orcid.org/0000-0003-1604-8714","observed_orcids":["https://orcid.org/0000-0003-1604-8714"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Anne Flint","raw_affiliation_strings":["Novo Nordisk, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028410710","display_name":"Agnes Gasiorek","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Agnes Gasiorek","raw_affiliation_strings":["Novo Nordisk, M\u00e5l\u00f8v, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk, M\u00e5l\u00f8v, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052701298","display_name":"Arne Heydorn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Arne Heydorn","raw_affiliation_strings":["Novo Nordisk, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016003520","display_name":"Ania M. Jastreboff","orcid":"https://orcid.org/0000-0003-1446-0991","observed_orcids":["https://orcid.org/0000-0003-1446-0991"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ania M Jastreboff","raw_affiliation_strings":["Section of Endocrinology (Internal Medicine & Pediatrics) and Yale Obesity Research Center (Y-Weight), Yale School of Medicine, New Haven, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section of Endocrinology (Internal Medicine & Pediatrics) and Yale Obesity Research Center (Y-Weight), Yale School of Medicine, New Haven, CT, USA","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074736925","display_name":"Cassandra Key","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cassandra Key","raw_affiliation_strings":["San Antonio Clinical Research Unit, ICON, San Antonio, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"San Antonio Clinical Research Unit, ICON, San Antonio, TX, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103399046","display_name":"Signe Beck Petersen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Signe Beck Petersen","raw_affiliation_strings":["Novo Nordisk, M\u00e5l\u00f8v, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk, M\u00e5l\u00f8v, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038771299","display_name":"Andreas Vegge","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Andreas Vegge","raw_affiliation_strings":["Novo Nordisk, M\u00e5l\u00f8v, Denmark; Novo Nordisk, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk, M\u00e5l\u00f8v, Denmark; Novo Nordisk, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042776932","display_name":"Kasper Adelborg","orcid":"https://orcid.org/0000-0001-5639-7252","observed_orcids":["https://orcid.org/0000-0001-5639-7252"]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Kasper Adelborg","raw_affiliation_strings":["Novo Nordisk, S\u00f8borg, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novo Nordisk, S\u00f8borg, Denmark","institution_ids":["https://openalex.org/I189090001"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5020283181"],"corresponding_institution_ids":["https://openalex.org/I189090001"],"apc_list":{"value":7890,"currency":"USD","value_usd":7890},"apc_paid":null,"fwci":33.0738,"has_fulltext":false,"cited_by_count":95,"citation_normalized_percentile":{"value":0.99885839,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"406","issue":"10499","first_page":"149","last_page":"162"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.9380000233650208,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.9380000233650208,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.046799998730421066,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10489","display_name":"Regulation of Appetite and Obesity","score":0.012500000186264515,"subfield":{"id":"https://openalex.org/subfields/2807","display_name":"Endocrine and Autonomic Systems"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.968999981880188},{"id":"https://openalex.org/keywords/amylin-receptor-agonist","display_name":"amylin receptor agonist","score":0.9940000176429749},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.8069999814033508},{"id":"https://openalex.org/keywords/overweight","display_name":"overweight","score":0.9940000176429749},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.6710000038146973},{"id":"https://openalex.org/keywords/subcutaneous-administration","display_name":"subcutaneous administration","score":0.8140000104904175},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9089999794960022},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8930000066757202},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.8420000076293945},{"id":"https://openalex.org/keywords/gastrointestinal-side-effects","display_name":"gastrointestinal adverse effects","score":0.8100000023841858},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6190000176429749},{"id":"https://openalex.org/keywords/weight-change","display_name":"weight change","score":0.4830000102519989},{"id":"https://openalex.org/keywords/single-ascending-dose","display_name":"single ascending dose","score":0.6100000143051147},{"id":"https://openalex.org/keywords/multiple-ascending-dose","display_name":"multiple ascending dose","score":0.9539999961853027},{"id":"https://openalex.org/keywords/glp-1-receptor","display_name":"GLP-1 receptor","score":0.44200000166893005},{"id":"https://openalex.org/keywords/amylin","display_name":"amylin","score":0.8339999914169312}],"concepts":[{"id":"https://openalex.org/C2780705028","wikidata":"https://www.wikidata.org/wiki/Q424643","display_name":"Amylin","level":4,"score":0.9093903303146362},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.7205841541290283},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7039059996604919},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5513691902160645},{"id":"https://openalex.org/C185280430","wikidata":"https://www.wikidata.org/wiki/Q14909910","display_name":"Glucagon-like peptide 1 receptor","level":4,"score":0.42306554317474365},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3829675018787384},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3731900453567505},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.36712515354156494},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3241620659828186},{"id":"https://openalex.org/C165220095","wikidata":"https://www.wikidata.org/wiki/Q207524","display_name":"Islet","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000097789","descriptor_name":"Glucagon-Like Peptide-1 Receptor Agonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009765","descriptor_name":"Obesity","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D050177","descriptor_name":"Overweight","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058228","descriptor_name":"Islet Amyloid Polypeptide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D058228","descriptor_name":"Islet Amyloid Polypeptide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D065091","descriptor_name":"Amylin Receptor Agonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1016/s0140-6736(25)01185-7","doi":"https://doi.org/10.1016/s0140-6736(25)01185-7","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s0140-6736(25)01185-7","pdf_url":null,"source":{"id":"https://openalex.org/S49861241","display_name":"The Lancet","issn_l":"0099-5355","issn":["0099-5355","0140-6736","1474-547X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Lancet","raw_type":"journal-article"},{"id":"pmid:40550231","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/40550231","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Lancet (London, England)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320322436","display_name":"Novo Nordisk","ror":"https://ror.org/0435rc536"},{"id":"https://openalex.org/F5506174416","display_name":"Apollo","ror":null}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W2045554373","https://openalex.org/W2148897749","https://openalex.org/W2170571946","https://openalex.org/W2770514262","https://openalex.org/W2805436655","https://openalex.org/W2895135221","https://openalex.org/W2895666357","https://openalex.org/W2903677519","https://openalex.org/W3037705475","https://openalex.org/W3087889571","https://openalex.org/W3127371223","https://openalex.org/W3155125407","https://openalex.org/W3211623221","https://openalex.org/W3213283278","https://openalex.org/W3217337816","https://openalex.org/W4213087703","https://openalex.org/W4221048252","https://openalex.org/W4281934192","https://openalex.org/W4381885413","https://openalex.org/W4381953540","https://openalex.org/W4382049661","https://openalex.org/W4386154055","https://openalex.org/W4388592674","https://openalex.org/W4391262240","https://openalex.org/W4398759815","https://openalex.org/W4399907994","https://openalex.org/W4403667877","https://openalex.org/W4404437149","https://openalex.org/W4410277932","https://openalex.org/W4411475025","https://openalex.org/W4412605939"],"related_works":["https://openalex.org/W4411475025","https://openalex.org/W4411293830","https://openalex.org/W7138175458","https://openalex.org/W4414946695","https://openalex.org/W4414946694","https://openalex.org/W4412539733","https://openalex.org/W4412605939","https://openalex.org/W7162184960","https://openalex.org/W4414256313","https://openalex.org/W7203894389"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4411475014","counts_by_year":[{"year":2026,"cited_by_count":73},{"year":2025,"cited_by_count":22}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2025-10-10T00:00:00"}
